2025 Q2 -tulosraportti
200 päivää sitten1,9179 CHF/osake
Viimeisin osinko
1,67%Tuotto/v
Tarjoustasot
CBOE Europe
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
114,8VWAP
Alin
111,4VaihtoMäärä
0,3 2 840
VWAP
Ylin
114,8Alin
111,4VaihtoMäärä
0,3 2 840
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 9.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2025 H1 -tulosraportti | 23.7.2025 | |
| 2024 H2 -tulosraportti | 6.3.2025 | |
| 2024 Q4 -tulosraportti | 6.3.2025 | |
| 2024 Q2 -tulosraportti | 24.7.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
3.2.3.2.Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares Dublin, Ireland – February 3, 2026: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not result in dilution for existing shareholders. This investment represents one of the most significant institutional placements in Cosmo’s recent history and marks a major milestone in the Company’s ongoing transformation into a focused, innovation driven healthcare leader. The transaction further strengthens Cosmo’s shareholder base, enhances financial flexibility, and supports continued investment behind the Company’s strategic growth priorities across MedTech AI, dermatology, gastroenterology, and CDMO. Giovanni Di Napoli, Chief Executive Officer of Cosmo Pharmaceuticals, commented: “We see this transaction as an important step in accelerating our journey and delivering long term value for all shareholders. The investment was enabled by the progress we have made, the clarity of our Vision 2030 strategy, and our ambition to build a global healthcare innovation company at the intersection of therapeutics, digital platforms, and AI enabled MedTech.” Svetlana Sigalova, Chief Financial Officer of Cosmo Pharmaceuticals, added: “This transaction reflects a highly strategic and disciplined use of treasury shares. It reinforces the strength of our financial position and supports our long-term capital allocation priorities as we continue to invest behind innovation, growth, and strategic execution.” The transaction was conducted as a private placement with a single institutional investor. The shares are fully fungible with existing listed shares and rank pari passu in all respects. In accordance with applicable regulations, Cosmo will be filing the relevant major shareholding notifications with SIX Swiss Exchange
·16.12.2025Have taken a starting position in Cosmo. The case for me is especially "clascoterone" 5% for male pattern baldness – a topical DHT blocker with strong Phase III topline data. If 12-month safety holds and FDA/EMA submission succeeds, it could become the first real alternative to finasteride without systemic side effects. There is huge potential!
·16.12.2025Woman who cheers for that! Understands well that hair loss in men is really sh*t and painful - especially for those who get it when they are still young.
·9.12.2025Does one think this can explode similarly to novo nordisk during the Ozempic hype?
·12.12.2025Cosmo is now undergoing the mandatory 12-month safety follow-up, which is expected to be completed in spring 2026. Subsequently, the company plans to submit parallel regulatory applications to both the U.S. Food and Drug Administration FDA and the European Medicines Agency EMA. If the approvals come as planned, the treatment could reach pharmacies in 2027.
·8.12.2025👨🦲💸
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
200 päivää sitten1,9179 CHF/osake
Viimeisin osinko
1,67%Tuotto/v
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3.2.3.2.Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares Dublin, Ireland – February 3, 2026: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not result in dilution for existing shareholders. This investment represents one of the most significant institutional placements in Cosmo’s recent history and marks a major milestone in the Company’s ongoing transformation into a focused, innovation driven healthcare leader. The transaction further strengthens Cosmo’s shareholder base, enhances financial flexibility, and supports continued investment behind the Company’s strategic growth priorities across MedTech AI, dermatology, gastroenterology, and CDMO. Giovanni Di Napoli, Chief Executive Officer of Cosmo Pharmaceuticals, commented: “We see this transaction as an important step in accelerating our journey and delivering long term value for all shareholders. The investment was enabled by the progress we have made, the clarity of our Vision 2030 strategy, and our ambition to build a global healthcare innovation company at the intersection of therapeutics, digital platforms, and AI enabled MedTech.” Svetlana Sigalova, Chief Financial Officer of Cosmo Pharmaceuticals, added: “This transaction reflects a highly strategic and disciplined use of treasury shares. It reinforces the strength of our financial position and supports our long-term capital allocation priorities as we continue to invest behind innovation, growth, and strategic execution.” The transaction was conducted as a private placement with a single institutional investor. The shares are fully fungible with existing listed shares and rank pari passu in all respects. In accordance with applicable regulations, Cosmo will be filing the relevant major shareholding notifications with SIX Swiss Exchange
- ·16.12.2025Have taken a starting position in Cosmo. The case for me is especially "clascoterone" 5% for male pattern baldness – a topical DHT blocker with strong Phase III topline data. If 12-month safety holds and FDA/EMA submission succeeds, it could become the first real alternative to finasteride without systemic side effects. There is huge potential!·16.12.2025Woman who cheers for that! Understands well that hair loss in men is really sh*t and painful - especially for those who get it when they are still young.
- ·9.12.2025Does one think this can explode similarly to novo nordisk during the Ozempic hype?·12.12.2025Cosmo is now undergoing the mandatory 12-month safety follow-up, which is expected to be completed in spring 2026. Subsequently, the company plans to submit parallel regulatory applications to both the U.S. Food and Drug Administration FDA and the European Medicines Agency EMA. If the approvals come as planned, the treatment could reach pharmacies in 2027.
- ·8.12.2025👨🦲💸
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
CBOE Europe
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
114,8VWAP
Alin
111,4VaihtoMäärä
0,3 2 840
VWAP
Ylin
114,8Alin
111,4VaihtoMäärä
0,3 2 840
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 9.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2025 H1 -tulosraportti | 23.7.2025 | |
| 2024 H2 -tulosraportti | 6.3.2025 | |
| 2024 Q4 -tulosraportti | 6.3.2025 | |
| 2024 Q2 -tulosraportti | 24.7.2024 |
2025 Q2 -tulosraportti
200 päivää sittenUutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 9.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2025 H1 -tulosraportti | 23.7.2025 | |
| 2024 H2 -tulosraportti | 6.3.2025 | |
| 2024 Q4 -tulosraportti | 6.3.2025 | |
| 2024 Q2 -tulosraportti | 24.7.2024 |
1,9179 CHF/osake
Viimeisin osinko
1,67%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3.2.3.2.Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares Dublin, Ireland – February 3, 2026: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not result in dilution for existing shareholders. This investment represents one of the most significant institutional placements in Cosmo’s recent history and marks a major milestone in the Company’s ongoing transformation into a focused, innovation driven healthcare leader. The transaction further strengthens Cosmo’s shareholder base, enhances financial flexibility, and supports continued investment behind the Company’s strategic growth priorities across MedTech AI, dermatology, gastroenterology, and CDMO. Giovanni Di Napoli, Chief Executive Officer of Cosmo Pharmaceuticals, commented: “We see this transaction as an important step in accelerating our journey and delivering long term value for all shareholders. The investment was enabled by the progress we have made, the clarity of our Vision 2030 strategy, and our ambition to build a global healthcare innovation company at the intersection of therapeutics, digital platforms, and AI enabled MedTech.” Svetlana Sigalova, Chief Financial Officer of Cosmo Pharmaceuticals, added: “This transaction reflects a highly strategic and disciplined use of treasury shares. It reinforces the strength of our financial position and supports our long-term capital allocation priorities as we continue to invest behind innovation, growth, and strategic execution.” The transaction was conducted as a private placement with a single institutional investor. The shares are fully fungible with existing listed shares and rank pari passu in all respects. In accordance with applicable regulations, Cosmo will be filing the relevant major shareholding notifications with SIX Swiss Exchange
- ·16.12.2025Have taken a starting position in Cosmo. The case for me is especially "clascoterone" 5% for male pattern baldness – a topical DHT blocker with strong Phase III topline data. If 12-month safety holds and FDA/EMA submission succeeds, it could become the first real alternative to finasteride without systemic side effects. There is huge potential!·16.12.2025Woman who cheers for that! Understands well that hair loss in men is really sh*t and painful - especially for those who get it when they are still young.
- ·9.12.2025Does one think this can explode similarly to novo nordisk during the Ozempic hype?·12.12.2025Cosmo is now undergoing the mandatory 12-month safety follow-up, which is expected to be completed in spring 2026. Subsequently, the company plans to submit parallel regulatory applications to both the U.S. Food and Drug Administration FDA and the European Medicines Agency EMA. If the approvals come as planned, the treatment could reach pharmacies in 2027.
- ·8.12.2025👨🦲💸
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
CBOE Europe
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
114,8VWAP
Alin
111,4VaihtoMäärä
0,3 2 840
VWAP
Ylin
114,8Alin
111,4VaihtoMäärä
0,3 2 840
Välittäjätilasto
Dataa ei löytynyt